125. Eur J Cancer. 2018 Jun;96:17-24. doi: 10.1016/j.ejca.2018.03.015. Epub 2018 Apr13.Time trends of overall survival among metastatic breast cancer patients in thereal-life ESME cohort.Gobbini E(1), Ezzalfani M(2), Dieras V(3), Bachelot T(4), Brain E(3), DebledM(5), Jacot W(6), Mouret-Reynier MA(7), Goncalves A(8), Dalenc F(9), PatsourisA(10), Ferrero JM(11), Levy C(12), Lorgis V(13), Vanlemmens L(14),Lefeuvre-Plesse C(15), Mathoulin-Pelissier S(16), Petit T(17), Uwer L(18),Jouannaud C(19), Leheurteur M(20), Lacroix-Triki M(21), Cleaud AL(2), RobainM(22), Courtinard C(22), Cailliot C(22), Perol D(2), Delaloge S(23).Author information: (1)Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800Villejuif, France.(2)Department of Biostatistics, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008 Lyon, France.(3)Department of Medical Oncology, Institut Curie, 26 Rue D'Ulm, 75005 Paris &Saint-Cloud, France.(4)Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et NapoléonBullukian, 69008 Lyon, France.(5)Department of Medical Oncology, Institut Bergonié, 229 Cours de L'Argonne,33000 Bordeaux, France.(6)Department of Medical Oncology, Institut Du Cancer de Montpellier, 208 Rue desApothicaires, 34298 Montpellier, France.(7)Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011Clermont Ferrand, France.(8)Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard deSainte-Marguerite, 13009 Marseille, France.(9)Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1Avenue Irène-Joliot-Curie, 31059 Toulouse, France.(10)Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes & Angers, 15 rue André Boquel, 49055 Angers, France.(11)Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue deValambrose, 06189 Nice, France.(12)Department of Medical Oncology, Centre François Baclesse, 3 Avenue du GénéralHarris, 14000 Caen, France.(13)Department of Medical Oncology, Centre Georges François Leclerc, 1 rueProfesseur Marion, 21079 Dijon, France.(14)Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France.(15)Medical Oncology Department, Centre Eugéne Marquis, Avenue de la BatailleFlandres-Dunkerque, 35000 Rennes, France.(16)INSERM CIC1401, Institut Bergonie, Comprehensive Cancer Center, F-33000Bordeaux, France.(17)Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte del'Hôpital, 67000 Strasbourg, France.(18)Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100 Reims, France.(19)Medical Oncology Department, Institut de Cancérologie de Lorraine,Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.(20)Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000Rouen, France.(21)Department of BioPathology, Gustave Roussy, 114 Rue Edouard Vaillant, 94800Villejuif, France.(22)Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac,75654 Paris, France.(23)Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant,94800 Villejuif, France. Electronic address: suzette.delaloge@gustaveroussy.fr.AIM: Real-life analysis of overall survival (OS) trends among metastatic breastcancer (MBC) patients may help define medical needs and evaluate the impact ofpublic health investments. The present study aimed to evaluate the independentimpact of the year of MBC diagnosis on OS in theEpidemio-Strategy-Medical-Economical (ESME)-MBC cohort.METHODS: ESME-MBC (NCT03275311) is a French, national, multicentre, observationalcohort including 16,702 consecutive newly diagnosed MBC patients (01 January2008-31 December 2014). Of 16,680 eligible patients, 15,085 had fullimmunohistochemistry data, allowing classification as hormone receptor-positiveand HER2-negative (HR+/HER2-, N = 9907), HER2-positive (HER2+, N = 2861) ortriple-negative (HR-/HER2-, N = 2317) subcohorts. Multivariate analyses of OSwere conducted among the full ESME cohort and subcohorts.RESULTS: Median OS of the whole cohort was 37.22 months (95% confidence interval [CI], 36.3-38.04). Year of diagnosis was an independent predictor of OS (hazardratio 0.98 [95% CI, 0.97-1.00], P = .01) together with age, subtype, disease-freeinterval, visceral metastases and number of organs involved. Median OS ofHR+/HER2-, HER2+ and HR-/HER2- subcohorts was, respectively, 42.12 (95% CI,40.90-43.10), 44.91 (95% CI, 42.51-47.90) and 14.52 (95% CI, 13.70-15.24) months.Year of diagnosis was a strong independent predictor of OS in HER2+ subcohort(hazard ratio 0.91 [95% CI, 0.88-0.94], P < .001), but not in HR+/HER2- norHR-/HER2- subcohorts (hazard ratio 1.00 [95% CI, 0.98-1.01], P = .80 and 1.00[95% CI, 0.97-1.02], P = .90, respectively).CONCLUSIONS: The OS of MBC patients has slightly improved over the past decade.However, this effect is confined to HER2+ cases, highlighting the need of newstrategies in the other subtypes.Copyright © 2018 Elsevier Ltd. All rights reserved.DOI: 10.1016/j.ejca.2018.03.015 PMID: 29660596 